New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - orphenadrine citrate 100mg - tablet - 100 mg - active: orphenadrine citrate 100mg excipient: colloidal silicon dioxide ethylcellulose lactose monohydrate magnesium stearate - norflex (orphenadrine citrate) is indicated for the relief of stiffness and pain resulting from skeletal muscle spasm in sprains and strains, local muscle injury, prolapsed intervertebral disc, lumbago, fibrositis, non-articular rheumatism, acute torticollis, surgery, fractures, anxiety and tension. orphenadrine citrate has also been shown to be effective for treatment of tension headache and persistent hiccoughs.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - fluorouracil 5%;   - topical cream - 5 % - active: fluorouracil 5%   excipient: methyl hydroxybenzoate polysorbate 60 propyl hydroxybenzoate propylene glycol purified water stearyl alcohol white soft paraffin - efudix is used for the topical treatment of superficial pre-malignant and malignant skin lesions; keratoses including senile, actinic and arsenical forms; keratoacanthoma; bowen's disease; superficial basal-cell carcinoma. deep, penetrating or nodular basal cell and squamous cell carcinomas do not usually respond to efudix therapy. it should be used only as a palliative therapy in such cases where no other form of treatment is possible.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - bupropion hydrochloride 90mg equivalent to bupropion 78mg;  ;  ; naltrexone hydrochloride 8mg equivalent to naltrexone 7.2mg;   - modified release tablet - active: bupropion hydrochloride 90mg equivalent to bupropion 78mg     naltrexone hydrochloride 8mg equivalent to naltrexone 7.2mg   excipient: colloidal silicon dioxide crospovidone cysteine hydrochloride monohydrate disodium edetate hyprolose hypromellose indigo carmine aluminium lake lactose lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90663 - contrave is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (>/= 18 years) with an initial body mass index (bmi) of: · >/= 30 kg/m2 (obese), or · >/= 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). treatment with contrave should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - nefopam hydrochloride 30mg;   - tablet - 30 mg - active: nefopam hydrochloride 30mg   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide hydrogenated vegetable oil hypromellose magnesium stearate microcrystalline cellulose starch titanium dioxide - acupan is indicated for the relief of acute pain, including post-operative, dental, musculo-skeletal and acute traumatic pain.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - phentermine 15mg (as an ion exchange resin);  ; phentermine 15mg (as an ion exchange resin) - modified release capsule - 15 mg - active: phentermine 15mg (as an ion exchange resin)   excipient: brilliant blue fcf gelatin iron oxide yellow lactose monohydrate liquid paraffin magnesium stearate titanium dioxide vegetable carbon active: phentermine 15mg (as an ion exchange resin) excipient: brilliant blue fcf gelatin iron oxide black iron oxide yellow lactose monohydrate liquid paraffin magnesium stearate titanium dioxide - duromine is indicated as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based on exercise, diet (caloric restriction) and behaviour modification in obese patients with a body mass index (bmi) or 30kg/m2 or greater who have not achieved an adequate clinical response to an appropriate weight-reducing regimen alone. duromine may appropriately be initiated in overweight patients with a lower bmi when risk of morbidity from other medical conditions is increased. patients with the following co-morbidities are particular candidates for medical assistance with weight reduction, and may be considered for treatment even if their bmi does not exceed 30 kg/m2: · sleep apnoea, · insulin-resistant diabetes mellitus, · pre-diabetes or impaired glucose tolerance in association with obesity, · high cardiovascular risk status as a consequence of obesity failure to achieve a weight reduction of 5% within a period of 12 weeks is an indication for discontinuation of treatment. treatment may continue beyond this point provided continued monitoring of the patient occurs (for weight loss and medical conditions) and for as long as weight lossis maintained. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - phentermine 30mg (as an ion exchange resin);  ; phentermine 30mg (as an ion exchange resin) - modified release capsule - 30 mg - active: phentermine 30mg (as an ion exchange resin)   excipient: gelatin iron oxide red lactose monohydrate liquid paraffin magnesium stearate titanium dioxide vegetable carbon active: phentermine 30mg (as an ion exchange resin) excipient: gelatin iron oxide black iron oxide red lactose monohydrate liquid paraffin magnesium stearate titanium dioxide - duromine is indicated as a short-term adjunct in a medically monitored comprehensive regimen of weight reduction based on exercise, diet (caloric restriction) and behaviour modification in obese patients with a body mass index (bmi) or 30kg/m2 or greater who have not achieved an adequate clinical response to an appropriate weight-reducing regimen alone. duromine may appropriately be initiated in overweight patients with a lower bmi when risk of morbidity from other medical conditions is increased. patients with the following co-morbidities are particular candidates for medical assistance with weight reduction, and may be considered for treatment even if their bmi does not exceed 30 kg/m2: · sleep apnoea, · insulin-resistant diabetes mellitus, · pre-diabetes or impaired glucose tolerance in association with obesity, · high cardiovascular risk status as a consequence of obesity failure to achieve a weight reduction of 5% within a period of 12 weeks is an indication for discontinuation of treatment. treatment may continue beyond this point provided continued monitoring of the patient occurs (for weight loss and medical conditions) and for as long as weight lossis maintained. secondary organic causes of obesity should be excluded by diagnosis before prescribing this agent.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - theophylline 5.33 mg/ml;  ;   - syrup - 80 mg/15ml - active: theophylline 5.33 mg/ml     excipient: berry citrus blend aa001115 flavour methyl hydroxybenzoate propyl hydroxybenzoate purified water sorbitol sucrose

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - theophylline 250mg;  ; theophylline 250mg - modified release tablet - 250 mg - active: theophylline 250mg   excipient: cellacefate lactose monohydrate magnesium stearate active: theophylline 250mg excipient: guar gum magnesium stearate - nuelin-sr tablets are indicated for the relief and prophylaxis of reversible bronchospasm associated with asthma, chronic bronchitis and emphysema.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - flecainide acetate 10 mg/ml;   - solution for injection - 10 mg/ml - active: flecainide acetate 10 mg/ml   excipient: glacial acetic acid sodium acetate trihydrate water for injection - tambocor injection is indicated in patients without structural heart disease when rapid control or short-term prophylaxis of the arrhythmias below is the main clinical requirement, including: · ventricular tachyarrhythmias where these are resistant to other treatment; · av nodal reciprocating tachycardia, arrhythmias associated with wolff-parkinson-white syndrome and similar conditions with accessory pathways; · paroxysmal atrial fibrillation in patients with disabling symptoms. arrhythmias of recent onset will respond more readily.

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - flecainide acetate 100mg;   - tablet - 100 mg - active: flecainide acetate 100mg   excipient: croscarmellose sodium hydrogenated vegetable oil magnesium stearate microcrystalline cellulose pregelatinised maize starch - supraventricular arrhythmias -paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; -paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms.